VIV:CC News and Press, Avivagen Inc. From 08/19/22

VIV:CC - Avivagen Announces New Dairy Customer in Mexico

*Family-owned dairy business with established reputation for high-quality products turning to OxC-beta™ to support quality of milk * Order procured through Meyenberg International, Avivagen’s Mexican distribution partner Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ...

VIV:CC - Avivagen Announces Receipt of Repeat Order from Asian Customer

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

VIV:CC - Avivagen Announces Significant Order of OxC-beta(TM) in Brazil

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

VIV:CC - Avivagen Announces Sales of Companion Animal Product and Management Change

6,000 pouches ordered via new and existing customers in Taiwan and Mexico Chris Boland departs role as Chief Financial Officer Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing ...

VIV:CC - Avivagen Inc. Announces Closing of Third Tranche of a Private Placement of Shares and Warrants

Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby ...

VIV:CC - Avivagen Inc. Announces Options Grant

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

VIV:CC - Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2022

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

VIV:CC - Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

VIV:CC - Avivagen Provides Second Update on Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”) announces that the TSX Venture Exchange has granted a second extension of up to ...

VIV:CC - Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares and Warrants for Proceeds of Up to $5.0 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”), a life sciences corporation focused on developing and commercializing products ...

Company Name:	Avivagen Inc.
Stock Symbol:	VIV:CC
Market:	TSXVC